This article described a recent study about green tea’s possible impact on cancer and cardiovascular disease. While it raised questions about tea quality and how that might affect the results obtained, no data were given to support the conclusion about which teas would provide the desired benefit. There was nothing in the piece about other things that could account for the findings (eg, healthy habits, genetics), or whether there were other lines of evidence to support this association. There was also no quantification of benefit nor any comparison with other ways to reduce cardiovascular disease risk. A discussion of patterns of eating and drinking in different cultures and the effect of these patterns on disease incidence in populations would have been useful to help the reader put the study results in context.
Although this article did a good job towards the end of explaining the nature of the study from which the information was derived and the limitations of the conclusions that should be drawn, the tone of the article was that green tea was of benefit and that there are finally data to support this contention.
There are no costs mentioned with the type of tea recommended in the article (gyokuro or matcha) though the article suggests vendors of these types of tea. If the story can suggest sellers, it can cover costs, which can vary widely with these products.
The benefits of drinking 5 or more cups of green tea a day was presented as a decreased chance of dying in the 11 year period of the study. However, there was no information about the amount that risk decreased. Although increased green tea consumption was seen to be associated with decreased risk of death from heart disease, the percentage of individuals dying of heart disease was less than half the number in Americans of comparable age. It is difficult to know the meaning of this difference.
There is no evidence presented about the how the type of green tea may influence the outcome of cardiovascular mortality, only that the larger amount of green tea consumed was associated with decreased cardiovascular mortality.
A claim is made in the article that by enjoying tea of the best quality, you are probably doing more good than harm. The article did not mention any potential harms associated with consumption of green tea, even if that would be to say that there are no known risks associated with green tea consumption.
Although the article did mention that the common green teas found in the U.S. may differ in ways that could affect their potential health benefits, no evidence was given that components in the green tea consumed in Japan were associated with the effects observed.
At the end of the article, there is an informative paragraph explaining the type of study from which the data were derived (prospective population study) and that the suppositions still remain to be tested in controlled conditions. It is important for readers to understand that as the study cited was a cohort study, the issue of potential confounders such as diet or other health relevant behaviors might have had a role in the benefits observed. Further, there may also be genetic differences between populations that could affect whether green tea consumption affects health outcomes. The tone of the article was that green tea was of benefit and that there is finally data to support this contention.
Cancer and cardiovascular disease (two major causes of death in the U.S.) are not hyped.
There are no quotes from any investigators in the field. Even if Dr. Weil’s expertise is taken into account as author of the piece, that is still only a single-source perspective.
The article did not mention other ways to decrease cardiovascular mortality risk.
The article discusses differences in the green tea typically available in Japan and in the United States and offers suggestion sabout where Japanese green tea can be obtained. But the suggestion that the results of the study derive only from Japanese green tea and not green tea available in the US is not justified by the study cited.
This article is not about a novel treatment but was stimulated by the results of one recent study.
This article does not appear to rely on a press release.
Systematic, Criteria-Driven
We’ve written about the hype of liquid biopsies for years (see link in comment below). And now this…. https://www.statnews.com/2022/01/12/medicare-shouldnt-cover-liquid-biopsies-early-cancer-detection/
Case counts still matter. “(There) are stories that may not be told adequately if only hospitalizations and deaths are emphasized.” @garyschwitzer interviewed by @dbauder of @AP. https://apnews.com/article/omicron-changing-news-outlets-covid-data-da9272f7c4c8a109c3bfb56bed9e9c76
My friend Gary @garyschwitzer wrote to his city council representative in a Minnesota town about a Viva Las Vegas event scheduled for January.
The response he got seems to perfectly capture where we are now.
https://www.healthnewsreview.org/2021/12/2021-ends-with-covid-craziness-in-sports-and-politics/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like